RACGP
Medical Forum Logo

Medical Forum

Call for more clarity in new Heart Foundation guidelines

The RACGP wants to see a number of points within Australia’s proposed new blood pressure and hypertension guidelines clarified before implementation.

US approves WA-trialled drug

It has been a decade since the Heart Foundation’s guidance was updated, so the 2027 update is expected to include a lot of new detail. However, the RACGP has said the clarity, consistency and clinical utility of the current draft could be strengthened.

It has put forward a number of proposed amendments as part of the consultation process into the Heart Foundation’s Australian ‘Guideline for the diagnosis and management of elevated blood pressure and hypertension in adults’.

Among the changes to be incorporated are some regarding screening for primary aldosteronism at the time of diagnosis, a lowering of treatment thresholds, use of combination pharmacotherapy and shorter up-titration timelines.

The RACGP's submission queried the recommended testing sequence for urinary protein screening, which the guidelines suggest should begin with dipstick testing, saying it differs "from the general principle underpinning many screening programs".

The College also called for more explicit guidance regarding monitoring of renal function and for the inclusion of detail on how a group designated a "priority population" translates into practical guidance for clinicians.

The RACGP has also listed a number of areas in the draft where the presentation of information could have the potential to create uncertainty for clinicians.

AD

"The wording of some recommendations and flowcharts may inadvertently create the impression that pharmacotherapy should routinely be initiated following a diagnosis of hypertension," the submission states.

"The RACGP recommends the guideline clearly states that pharmacological treatment would not generally be indicated in younger adults in the absence of significant additional cardiovascular risk factors or blood pressure exceeding 180mmHg."

The College called for clear explanations with supporting evidence for pharmacotherapy treatment thresholds for the different risk groups.

"Clarification is also required regarding the rationale for maintaining separate treatment thresholds for systolic and diastolic blood pressure," the RACGP's submission reads.

"The guideline should clearly articulate the evidence for distinct thresholds and explain how clinicians should interpret situations where systolic and diastolic values indicate different treatment pathways."

The RACGP has also requested the Heart Foundation seek its endorsement of the final hypertension guidelines before release.

AD